GenMedPro

GenMedPro is a genetics-based medication management platform developed by Genomind for prescribers, pharmacists, and care teams. It is designed to evaluate medication therapy regimens by embedding pharmacogenomics (PGx) data, drug-drug interactions, gene-drug interactions, patient demographics, and social determinants of health within a single platform. The platform is intended to remain clinically relevant across a patient's lifetime as diagnoses expand, medications change, and polypharmacy increases.

GenMedPro works best in conjunction with Genomind's PGx test, which analyzes 26 genes that influence commonly prescribed medications across multiple specialties. The platform covers over 1,200 drugs, representing more than 99% of the most frequently prescribed medications, and supports both individual prescribers and large care populations.

Core Capabilities

• Analyzes 26 genes that impact medications across a range of clinical specialties.
• Assesses drug-drug and gene-drug interactions simultaneously within a single view.
• Incorporates patient demographics, social determinants of health, and genetic profile data together.
• Covers over 1,200 drugs, representing more than 99% of the most common prescriptions.
• Refreshes drug-drug and gene-drug interaction assessments at any time as new diagnoses emerge or medications are updated, rather than delivering a static one-time report.
• Surfaces polypharmacy risks in a consolidated view to support de-prescribing decisions and reduce medication waste.
• Identifies significant genetic and drug interactions upfront to help prevent adverse events and reduce unnecessary emergency department visits or hospital stays.

Clinical Use Cases

• Supports prescribers in evaluating current and future medication options based on a patient's genetic profile.
• Helps care teams adjust prescriptions based on genetic insights, such as identifying when a patient may require lower doses due to potential increases in drug serum levels.
• Provides outcome-level guidance per medication, indicating whether pharmacokinetic interactions are detected and recommending dosing adjustments where relevant.
• Applicable across patient age groups and conditions, including pediatric patients and those with complex, multi-medication regimens.
• Supports reduction of trial-and-error prescribing by surfacing evidence-based medication intelligence at the point of prescribing.

Platform Differentiation

• Unlike static PGx reports that address only gene-drug interactions in isolation, GenMedPro continuously updates interaction assessments as a patient's medication regimen evolves.
• Designed to handle the complexity of real-world prescribing, where patients are typically on multiple medications for multiple conditions.
• Integrates PGx data into everyday clinical workflows without requiring additional visit time, staffing, or operational resources.
• Scales across care settings, from individual practices to large population health programs.

Genetic Profile Data Displayed

• The platform displays results for multiple genes including CYP2B6, CYP2C19, CYP2D6, SLCO1B1, ABCB1 (PGP), ABCB1, ABCG2, CYP1A2, CYP2C9, HLA-A *31:01, and HLA-B *15:02, among others.
• Results are categorized by metabolizer or function status (e.g., rapid metabolizer, intermediate metabolizer, poor metabolizer, normal function, poor function) and used to generate per-medication outcome guidance.

GenMedPro is available with a free trial option and can be accessed via a demo. The platform is developed and maintained by Genomind, a company focused on pharmacogenetics testing and clinical decision support.